PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Long-acting antipsychotic medication may improve treatment for schizophrenia

UCLA study shows injectable drug given every two weeks works better than daily pill for those who have been recently diagnosed

2015-06-25
(Press-News.org) Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.

The problem is that many people don't continue taking their medication once their symptoms improve.

Now, a UCLA study has found that people who took a long-acting injectable form of risperidone -- one given every two weeks -- had a substantially lower risk for the symptoms returning than people who took the daily medication as a pill.

The study, which will be published June 24 in the journal JAMA Psychiatry, concluded that doctors should consider prescribing the long-lasting injectable medication much earlier in the course of treatment than they typically do today.

"We know that not taking antipsychotic medication is the single greatest modifiable risk factor for psychotic symptoms returning," said Kenneth Subotnik, an adjunct professor of psychiatry at the UCLA Semel Institute for Neuroscience and Human Behavior and the study's first author, adding that patients who have only recently developed the disease are especially susceptible to not taking their medication daily.

Although long-acting medications have been around since the 1970s, most previous studies have focused on patients who had experienced schizophrenia for many years. In those patients, the long-acting medications were not always a better alternative. The UCLA study focused specifically on patients who had recently developed the disorder.

"Individuals with a single episode of schizophrenia who have responded well to antipsychotic medication, even if they do understand they have a mental disorder, very often doubt whether medication continues to be necessary," said Keith Nuechterlein, a UCLA professor of psychiatry and senior author of the study.

The researchers followed 83 people recently diagnosed with schizophrenia for a one-year period. Half were given the daily oral form of risperidone and the others were given the long-acting injectable form. All interventions were given as part of the UCLA Aftercare Research Program.

The researchers found that patients taking the injectable medicine were much more likely to stick with their treatment than patients taking the oral form, and that the injectable did a better job of controlling psychotic symptoms. During the 12-month period, just 5 percent of those taking the injectable medication had their psychotic symptoms return, versus 33 percent of those taking the pill.

In addition, Subotnik said, the benefits appear to be greater than when given after individuals have had the disorder for many years, which indicates that the long-acting injectable should be offered to patients earlier in the course of schizophrenia.

Subotnik said another benefit of the injectable is that -- because it's administered at a doctor's office rather than taken at home -- doctors can more easily track whether patients are regularly taking the medication.

"Because of that, we had nearly perfect adherence to the long-acting form of risperidone," he said.

Analyzing the same group of people, the researchers also found that consistent adherence to antipsychotic medication led to improvements in the patients' cognitive functioning, Nuechterlein said. (Those results have been presented at a conference but not yet published.) And in a 2012 study led by the late George Bartzokis, a UCLA professor of psychiatry, MRI scans of some of these participants found that the long-acting medication also increased the amount of brain myelin, the coating on nerve fibers which, like insulation around a wire, improves communication between nerve cells. Myelination often decreases in people with schizophrenia, which leads to impairments in brain function and cognition.

Nuechterlein said the next stage of the research will be examining whether there are additional benefits of a long-acting injectable antipsychotic medication, and if it is just as effective if given only once a month instead of every two weeks.

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.

The problem is that many people don't continue taking their medication once their symptoms improve.

Now, a UCLA study has found that people who took a long-acting injectable form of risperidone -- one given every two weeks -- had a substantially lower risk for the symptoms returning than people who took the daily medication as a pill.

The study, which will be published June 24 in the journal JAMA Psychiatry, concluded that doctors should consider prescribing the long-lasting injectable medication much earlier in the course of treatment than they typically do today.

"We know that not taking antipsychotic medication is the single greatest modifiable risk factor for psychotic symptoms returning," said Kenneth Subotnik, an adjunct professor of psychiatry at the UCLA Semel Institute for Neuroscience and Human Behavior and the study's first author, adding that patients who have only recently developed the disease are especially susceptible to not taking their medication daily.

Although long-acting medications have been around since the 1970s, most previous studies have focused on patients who had experienced schizophrenia for many years. In those patients, the long-acting medications were not always a better alternative. The UCLA study focused specifically on patients who had recently developed the disorder.

"Individuals with a single episode of schizophrenia who have responded well to antipsychotic medication, even if they do understand they have a mental disorder, very often doubt whether medication continues to be necessary," said Keith Nuechterlein, a UCLA professor of psychiatry and senior author of the study.

The researchers followed 83 people recently diagnosed with schizophrenia for a one-year period. Half were given the daily oral form of risperidone and the others were given the long-acting injectable form. All interventions were given as part of the UCLA Aftercare Research Program.

The researchers found that patients taking the injectable medicine were much more likely to stick with their treatment than patients taking the oral form, and that the injectable did a better job of controlling psychotic symptoms. During the 12-month period, just 5 percent of those taking the injectable medication had their psychotic symptoms return, versus 33 percent of those taking the pill.

In addition, Subotnik said, the benefits appear to be greater than when given after individuals have had the disorder for many years, which indicates that the long-acting injectable should be offered to patients earlier in the course of schizophrenia.

Subotnik said another benefit of the injectable is that -- because it's administered at a doctor's office rather than taken at home -- doctors can more easily track whether patients are regularly taking the medication.

"Because of that, we had nearly perfect adherence to the long-acting form of risperidone," he said.

Analyzing the same group of people, the researchers also found that consistent adherence to antipsychotic medication led to improvements in the patients' cognitive functioning, Nuechterlein said. (Those results have been presented at a conference but not yet published.) And in a 2012 study led by the late George Bartzokis, a UCLA professor of psychiatry, MRI scans of some of these participants found that the long-acting medication also increased the amount of brain myelin, the coating on nerve fibers which, like insulation around a wire, improves communication between nerve cells. Myelination often decreases in people with schizophrenia, which leads to impairments in brain function and cognition.

Nuechterlein said the next stage of the research will be examining whether there are additional benefits of a long-acting injectable antipsychotic medication, and if it is just as effective if given only once a month instead of every two weeks.

The study's other authors were Laurie Casaus, Joseph Ventura, John Luo, Gerhard Hellemann, Denise Gretchen-Doorly and Stephen Marder, all of UCLA. The research was supported by grants from the National Institute of Mental Health (MH037705 and MH066286); supplementary funding and medication was provided by Janssen Scientific Affairs.

INFORMATION:



ELSE PRESS RELEASES FROM THIS DATE:

Alzheimer's disease works differently in patients with and without Down syndrome

2015-06-25
LEXINGTON, Ky. (Jun. 26, 2015) -- Researchers at the University of Kentucky's Sanders-Brown Center on Aging have completed a study that revealed differences in the way brain inflammation -- considered a key component of AD-- is expressed in different subsets of patients, in particular people with Down syndrome (DS) and AD. People with Down syndrome have a third copy of Chromosome 21, and that chromosome is the same one responsible for the production of a molecule called amyloid precursor protein. Amyloid overproduction can lead to brain plaques that are a cardinal feature ...

New NASA supercomputer model shows planet making waves in nearby debris disk

New NASA supercomputer model shows planet making waves in nearby debris disk
2015-06-25
A new NASA supercomputer simulation of the planet and debris disk around the nearby star Beta Pictoris reveals that the planet's motion drives spiral waves throughout the disk, a phenomenon that causes collisions among the orbiting debris. Patterns in the collisions and the resulting dust appear to account for many observed features that previous research has been unable to fully explain. "We essentially created a virtual Beta Pictoris in the computer and watched it evolve over millions of years," said Erika Nesvold, an astrophysicist at the University of Maryland, Baltimore ...

UCLA studies identify predictors of depression and PTSD among African-Americans, Latinos

2015-06-25
Chronic disease and mental health issues disproportionately affect low-income African-Americans, Latinos and Hispanics, according to the Centers for Disease Control and Prevention. Two new studies by the UCLA Center for Culture, Trauma and Mental Health Disparities shed light on the causes and impacts of this disparity. The first study, published online by the journal Psychological Trauma, analyzed certain types of negative experiences that may affect low-income African-Americans and Latinos. It found five specific environmental factors, which the researchers call "domains," ...

Tracking the genetic arms race between humans and mosquitoes

2015-06-25
Every time you put on bug spray this summer, you're launching a strike in the ongoing war between humans and mosquitoes -- one that is rapidly driving the evolution of the pests. Scientists studying mosquitoes in various types of environments in the United States and in Russia found that between 5 and 20 percent of a mosquito population's genome is subject to evolutionary pressures at any given time -- creating a strong signature of local adaptation to environment and humans. This means that individual populations are likely to have evolved resistance to whatever local ...

Brain scan can predict who responds best to certain treatment for OCD

2015-06-25
Tens of millions of Americans -- an estimated 1 to 2 percent of the population -- will suffer at some point in their lifetimes from obsessive-compulsive disorder, a disorder characterized by recurrent, intrusive, and disturbing thoughts (obsessions), and/or stereotyped recurrent behaviors (compulsions). Left untreated, OCD can be profoundly distressing to the patient and can adversely affect their ability to succeed in school, hold a job or function in society. One of the most common and effective treatments is cognitive-behavioral therapy, which aims to help patients ...

As siblings learn how to resolve conflict, parents pick up a few tips of their own

2015-06-25
URBANA, Ill. -- When children participated in a program designed to reduce sibling conflict, both parents benefited from a lessening of hostilities on the home front. But mothers experienced a more direct reward. As they viewed the children's sessions in real time on a video monitor and coached the kids at home to respond as they'd been taught, moms found that, like their kids, they were better able to manage their own emotions during stressful moments. "Parenting more than one child is stressful, and until now, there have been few ways to help parents deal with their ...

The quantum spin Hall effect is a fundamental property of light

2015-06-25
In a paper that crystalizes knowledge from a variety of experiments and theoretical developments, scientists from the RIKEN Center for Emergent Matter Science in Japan have demonstrated that the quantum spin Hall effect--an effect known to take place in solid state physics--is also an intrinsic property of light. Photons have neither mass nor charge, and so behave very differently from their massive counterparts, but they do share a property, called spin, which results in remarkable geometric and topological phenomena. The spin--a measure of the intrinsic angular momentum--can ...

Pre-empting pressure ulcers in individuals with spinal cord injury

2015-06-25
Pressure ulcers affect more than 2.5 million Americans annually and patients who have spinal cord injuries that impair movement are more vulnerable to ulcer development. Researchers at the University of Pittsburgh School of Medicine have devised a computational model that could enhance understanding, diagnosis and treatment of pressure ulcers related to spinal cord injury. The research publishing this week in PLOS Computational Biology, shows the results of virtual clinical trials that demonstrated that in order to effectively treat the lesions, anti-inflammatory measures ...

Revisiting the restriction of antibiotics

2015-06-25
Antibiotic resistance, and multi-drug resistance, is a major public health threat. A new study publishing in PLOS Computational Biology finds conditions where restricting certain antibiotics may increase the frequency of multiple drug resistance. Uri Obolski and Prof. Lilach Hadany and colleagues used a mathematical model and electronic medical records data to show that drug restriction may also lead to results opposite of those desired. Restriction might facilitate the spread of resistant pathogens, due to ineffective treatment with antibiotics that have high resistance ...

Poppies provide missing piece of morphine biosynthesis puzzle

2015-06-25
This news release is available in Japanese. Researchers studying poppy plants -- the natural source of pain-relieving alkaloids, such as morphine and codeine -- have identified a fusion gene that facilitates important, back-to-back steps in the plant's morphine-producing pathway. These findings, which build upon recent efforts to engineer the morphine biosynthesis pathway in yeast, complete the metabolic pathway for morphine and pave the way for cheaper, safer routes to producing the economically important drug without the need for cultivating poppy fields. For about ...

LAST 30 PRESS RELEASES:

Sulfated yeast rises to the challenge facing rare earth metals

Global analysis reveals how biochar supercharges composting and cuts greenhouse gases

Blocking a cellular switch could prevent lung-scarring disease

Planet formation depends on when it happens: UNLV model shows why

Deep sleep supports memory via brain fluid and neural rhythms

Biochar and iron additives show promise for reviving degraded peatlands and locking away carbon

Cancer cells reactivate embryo-like gene editors to fuel growth

AI analysis of world’s largest heart attack datasets opens way to new treatment strategies

Decoding dangers of Arctic sea ice with seismic, radar method

Counting bites with AI might one day help prevent childhood obesity

Utah chemists discover enzyme that could help build next-generation GLP-1 drugs

Surprising bacteria discovery links Hawaiʻi’s groundwater to the ocean

New grants for schools offer CPR training and resources to make campuses safer

30 NFL players urge fans to join Nation of Lifesavers, learn lifesaving CPR

Study finds humans outweigh climate in depleting Arizona's water supply

Old-school material could power quantum computing, cut data center energy use

Vanderbilt scientist tackles key roadblock for AI in drug discovery

Overheating bat boxes place bats in mortal danger during heatwaves

Study shows medical-legal partnerships aid recovery for patients with violent injuries

Learning the language of lasso peptides to improve peptide engineering

Social conflict among strongest predictors of teen mental health concerns

New framework can improve the planning stage of surgical quality improvement projects

Research shows anger, not fear, shifts political beliefs

Gale and Ira Drukier Prize in Children’s Health Research awarded to pediatric rheumatologist at Boston Children’s Hospital

UNF chemistry professor awarded NSF Grant to advance laser-based measurement technology

Research shows how Dust Bowl-type drought causes unprecedented productivity loss

Non-hibernating pikas' protein restriction tweaks their gut microbiome to help them survive the winter, when winter-active herbivores often struggle to find dietary protein

Not for hearing but for symbiosis

Disconnected cerebral hemisphere in epilepsy patients shows sleep-like state during wakefulness

Incentivizing risk to inspire investments in clean innovation for aviation

[Press-News.org] Long-acting antipsychotic medication may improve treatment for schizophrenia
UCLA study shows injectable drug given every two weeks works better than daily pill for those who have been recently diagnosed